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LETTER TO THE EDITOR
Detection of HBV DNA in Cerumen and Sera of Hbsag 
Negative Patients with Chronic Hepatitis B Infection 
 
 
Dear Editor, 
Chronic carriers of hepatitis infection are living 
throughout the world mostly in the South East of 
Asia.
1-5 Recent studies have shown that some HBsAg 
negative individuals may develop some sort of chronic 
hepatitis B which is detectable employing some new 
laboratory diagnosis techniques such as molecular 
tests.
6,7 In human during decades, HBV had many mu-
tations by which this virus has been able to escape 
from the immune system reactions so that HBV by far 
has changed its life style.
8,9 Considering such muta-
tions into account, it seems necessary to employ some 
new diagnostic techniques particularly some standard 
laboratory tests to detect HBV in human fluids such as 
serum, cerumen, semen etc. ELISA is the routine 
standard test for diagnosis of HBV in medical labora-
tories using HBsAg but there is some limitation for this 
test
10,11 hence the quantitative PCR is recommended.
12 
The current study was designed to evaluate the HBV 
either qualitatively or quantitatively in sera compared 
to ear cerumen as one non-invasive diagnosis method 
among both HBsAg negative and positive individuals 
in Ilam population using PCR, real time PCR and ELI-
SA. PCR or real time PCR for HBV detection using 
cerumen was preferred as compared to serum as it is 
inexpensive, non-invasive, useful in epidemiological 
studies and more convenient to be performed in the 
clinic. Totally, 70 HBV patients whose infection was 
definitely detected as the control and 70 healthy indi-
vidual without any history of HBV either clinically or 
documentary as the case group were randomly selected 
from those referring to the Blood Bank of Ilam, be-
tween January 2008 and January 2009. All sera were 
tested for HBsAg using ELISA while sera and ceru-
men samples were tested for the HBV DNA using 
PCR and real time PCR. ELISA was done according to 
the method described previously.
11  Mann-Whitney 
test was used to compare the median log HBV DNA in 
sera and cerumen. Association between the variables 
log HBV DNA in serum and cerumen was analysed 
using Spearman correlation. To indicate the im-
portance of real time PCR compared to ELISA, Wil-
coxon Signed Rank Test was used. Analysis was done 
using R software ver. 2.11.1. P value <0.05 was con-
sidered as significant throughout the study. 
Results showed that only 2 individuals (2.89%) 
from the healthy people were HBsAg positive by 
ELISA, while 4.3% of participants in this group had 
HBV DNA by PCR and real time PCR indicating that 
7% of individuals in case group were the chronic car-
riers of HBV (Table 1).  
PCR and real time PCR were found to be both su-
perior to the ELISA particularly when cerumen and 
serum were both tested. The mean DNA copy/ml for 
cerumen and serum was 1.56×10
6 and 5.459×10
5 re-
spectively. Kolciogu et al. who had studied 40 pa-
tients with chronic hepatitis B, reported that 12.5% of 
patients had HBV DNA in their creumen while 100% 
showed HBV DNA in their sera using real time 
PCR
13 which is not completely in agreement with our 
results in that the PCR and real time PCR results were 
similar. Goh, Eui-Kyung et al. had studied 30 patients 
Table 1: Demographic and biochemical characteristics of all subjects among two groups. 
 
 
Variables 
Groups P value
Control (HBsAg+)
(n=70) 
Case (HBsAg-) 
(n=70) 
Sex (male) (%)  38 (54.3)  41 (58.6)  0.60 
Marital status (married) (%)  48 (82.9)  50 (71.4)  0.107 
Age (Years) (Mean±SD)  32.4±6.5  29.2±5.9  0.003 
HBsAg+  70 (100)  2 (2.9)  <0.001 
Log Viral Load       
Serum HBV (Mean±SD)  12±4.8  0.75±2.9  <0.001
a 
Serum HBV (median & range)  10.9 (0-22.7)  0 (0-15.8)  <0.001
a 
Cerumen HBV (Mean±SD)   8.3±4.5  0.54±2.1  <0.001
a 
Cerumen (median & range)   8.6 (0-19.2)  0 (0-12.4)  <0.001
a 
a P value was computed using Mann-Whitney test HBV DNA in cerumen 
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who showed HBV DNA in their serum, and reported 
that 66.7% of those patients had HBV DNA in their 
cerumen as well.
12 The current study not only con-
firmed the ELISA results for all HBsAg positives; 
they all had HBV DNA in their sera and 87% of them 
showed HBV DNA in their cerumen, but also about 7 
% of healthy individuals in case group had HBV 
DNA taking them into account as chronic carriers of 
HBV. There was a significant difference between the 
mean copy of log HBV DNA in serum and cerumen 
(p<0.001) favoring the higher mean copy/ml in ceru-
men than serum. The difference between PCR and 
real time PCR was not statistically significant but this 
difference was significant for ELISA and PCR 
(p<0.05) indicating the importance of real time PCR 
compared to ELISA. 
Correlation coefficient between log HBV DNA in 
serum and cerumen of control group was 0.78 
(p<0.001) while was 0.99 in case group confirming 
that cerumen can be used for both PCR and real time 
PCR procedures when detection of occult infection is 
the case even more effectively than serum. Another 
important finding is stressing on this point that 
HBsAg screening is not as reliable as molecular tech-
niques in detecting HBV chronic carriers. On the oth-
er hand, it is merely important that exposure to the 
source of HBV infection is crucial in transmission of 
HBV, also not only with blood–derived products but 
also with cerumen and some body fluid like cerumen. 
As the this study could not cover the genetic varia-
tions of HBV DNA in cerumen and serum, further 
investigations are required to confirm the infectivity 
of human cerumen, as well as to determine the char-
acteristics of HBV present in cerumen. 
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